Financial Analysis

ACQUISITION Acquisition of BIOVECTRA On September 20, 2024, we acquired 100 percent of the stock of BIOVECTRA for total consideration paid of $915 million in cash. The acquisition expands our contract development and manufacturing organization. As a result of the acquisition, BIOVECTRA became a wholly-owned subsidiary of Agilent. Accordingly, the results of BIOVECTRA are included in Agilent's consolidated financial statements from the acquisition date. The BIOVECTRA acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded at their estimated fair values. We determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BIOVECTRAs net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction. Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the Life Sciences and Diagnostics Markets segment. Our acquisition of BIOVECTRA is tre …

BusinessCombinationDisclosureTextBlock · excerpt; the full note is in the filing

"18. COMMITMENTS AND CONTINGENCIES Other Purchase Commitments. Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, there are termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contract's termination period before such contract can be cancelled. Our contractual obligations with these suppliers under ""other purchase commitments"" were approximately $146 million. Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows."

CommitmentsAndContingenciesDisclosureTextBlock

The following table presents the companys total revenue and segment revenue disaggregated by geographical region: Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total (in millions) Year Ended October 31, 2025: Americas $ 1,337 $ 1,095 $ 374 $ 2,806 Europe 786 811 326 1,923 Asia Pacific 603 1,002 614 2,219 Total $ 2,726 $ 2,908 $ 1,314 $ 6,948 Year Ended October 31, 2024: Americas $ 1,157 $ 1,048 $ 368 $ 2,573 Europe 723 741 306 1,770 Asia Pacific 586 958 623 2,167 Total $ 2,466 $ 2,747 $ 1,297 $ 6,510 Year Ended October 31, 2023: Americas $ 1,333 $ 1,003 $ 396 $ 2,732 Europe 729 701 324 1,754 Asia Pacific 718 952 677 2,347 Total $ 2,780 $ 2,656 $ 1,397 $ 6,833 The following table presents the companys total revenue disaggregated by end markets and by revenue type: Years Ended October 31, 2025 2024 2023 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 2,507 $ 2,242 $ 2,433 Chemicals and Advanced Materials 1,561 1,495 1,543 Diagnostics and Clinical 1,029 964 966 Food 637 592 628 Academia and Government 540 567 601 Environmental and Forensics 674 650 662 Total $ 6,948 $ 6,510 $ 6,833 Revenue by Type Instrumentation $ 2,427 $ 2,354 $ 2,742 Non-instrumentation and other 4,521 4,156 4,091 Total $ 6,948 $ 6,510 $ 6,833 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

"SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, employee stock options, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan (""LTPP"") based on estimated fair values. Description of Share-Based Plans Employee Stock Purchase Plan. Effective May 1, 2020, we adopted the 2020 Employee Stock Purchase Plan (""ESPP"") which replaced our previous Employee Stock Purchase Plan. The ESPP allows eligible employees to contribute up to 10 percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. There are 31 million shares authorized for issuance in connection with the ESPP. Under our ESPP, employees purchased 566,815 shares for $57 million in 2025, 576,467 shares for $58 million in 2024 and 487,735 shares for $57 million in 2023. As of October 31, 2025, the number of shares of common stock authorized and available for issuance under our ESPP was 23,234,771. This includes 223,241 shares for $28 million of common stock to be settled in November 2025 to participants in consideration of the aggregate participant contributions as of Oc …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 applies to ass …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

"GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2024 and 2025: Life Sciences and Diagnostics Markets Agilent Crosslab Applied Markets Total (in millions) Goodwill as of October 31, 2023 $ 2,489 $ 1,166 $ 305 $ 3,960 Foreign currency translation impact (15) 2 4 (9) Goodwill arising from acquisitions and adjustments 526 526 Goodwill as of October 31, 2024 $ 3,000 $ 1,168 $ 309 $ 4,477 Foreign currency translation impact 1 1 Goodwill arising from acquisitions and adjustments (5) (5) Goodwill as of October 31, 2025 $ 2,996 $ 1,168 $ 309 $ 4,473 In the first quarter of fiscal year 2025, we reorganized our operating segments; see Note 22, ""Segment Information"" for additional information about our segment reorganization. As a result, we used the relative fair value allocation approach to reassign approximately $1.274 billion of goodwill from our Applied Markets segment (formerly our Life Sciences and Applied Markets segment) to our Agilent CrossLab and Life Sciences and Diagnostics Markets segments. Of the $1.274 billion goodwill reallocated, $365 million was reassigned to Life Sciences and Diagnostics Markets segment and $909 million was reassigned to Agilent CrossLab segment. Goodwill balances as of October 31, 2023 and 2024, have been recast to conform to this new presentation. As a result of the reorganization, our reporting units are: Life Sciences and …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

"INCOME TAXES The domestic and foreign components of income before taxes are: Years Ended October 31, 2025 2024 2023 (in millions) U.S. operations $ 292 $ 391 $ 614 Non-U.S. operations 1,143 1,130 725 Total income before taxes $ 1,435 $ 1,521 $ 1,339 The provision for income taxes is comprised of: Years Ended October 31, 2025 2024 2023 (in millions) U.S. federal taxes: Current $ 103 $ 182 $ 117 Deferred (105) (104) (84) Non-U.S. taxes: Current 148 87 26 Deferred (16) 60 38 State taxes, net of federal benefit: Current 11 27 12 Deferred (9) (20) (10) Total provision for income taxes $ 132 $ 232 $ 99 The differences between the U.S. federal statutory income tax rate and our effective tax rate are: Years Ended October 31, 2025 2024 2023 (in millions) Profit before tax times statutory rate $ 301 $ 319 $ 281 State income taxes, net of federal benefit 3 7 2 Non-U.S. income taxed at different rates (40) (14) 20 Change in unrecognized tax benefits (37) (8) (35) Foreign-derived intangible income deduction (29) (47) (41) Realized loss on divestiture of business (104) Intra-entity transfer of assets (57) Other, net (9) (25) (24) Provision (benefit) for income taxes $ 132 $ 232 $ 99 Effective tax rate 9.2 % 15.3 % 7.4 % For 2025, our income tax expense was $132 million with an effective tax rate of 9.2 percent. For the year ended October 31, 2025, our effective tax rate and the resulting provision for income taxes were impacted by the federal tax benefit of $57 million related to the intr …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

"LEASES As a lessee, we have various non-cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years. The components of lease cost for operating leases were as follows: Year Ended October 31, 2025 2024 2023 (in millions) Operating lease cost $ 55 $ 58 $ 68 Short-term lease cost 1 2 Variable lease cost (a) 12 15 16 Sublease income (17) (17) (16) Total lease cost $ 51 56 70 (a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes. In the fourth quarter of fiscal year 2023, we initiated a new restructuring plan (""FY23 Plan"") d …

LesseeOperatingLeasesTextBlock · excerpt; the full note is in the filing

"LONG-TERM DEBT Senior Notes The following table summarizes the company's long-term senior notes: October 31, 2025 October 31, 2024 Amortized Principal Amortized Principal (in millions) 2026 Senior Notes $ $ 299 2027 Senior Notes 597 596 2029 Senior Notes 497 496 2030 Senior Notes 498 497 2031 Senior Notes 845 845 2034 Senior Notes 593 593 Total Senior Notes $ 3,030 $ 3,326 2026 Senior Notes On September 22, 2016, we issued aggregate principal amount of $300 million in senior notes (""2026 senior notes""). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017. In 2025, we reclassified the 2026 senior notes to short-term debt. In February 2016, we executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2025 was $1 mill …

LongTermDebtTextBlock · excerpt; the full note is in the filing

"RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS General. We have various defined benefit and defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Agilent provides defined benefits to U.S. employees who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the ""RP""). Effective November 1, 2014, Agilents U.S. RP was closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. As of April 30, 2016, benefits under the RP were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016, remained fully vested and is payable on termination, retirement, death, or permanent disability, based on an eligible participants years of credited service, age and other criteria. There are no additional benefit accruals after April 30, 2016. For eligible service through October 31, 1993, the benefit payable under the Agilent RP is reduced by any amounts due to the eligible employee under the Agilent Technologies, Inc. Deferred Profit-Sharing Plan (the ""DPSP""), which is a defined contribution plan that was frozen and closed to new participants as of November 1993. As of October 31, 2025 and 2024, the fair value of plan assets of the DPSP was $71 million and $74 million, respectively. The projected benefit obligation for the DPSP equals the fair value of plan assets. Agilent also maintains a Supplemental Benefit Retirement Plan (""SBRP …

PensionAndOtherPostretirementBenefitsDisclosureTextBlock · excerpt; the full note is in the filing

"RESTRUCTURING AND OTHER RELATED COSTS Summary of Restructuring Plans. In fiscal year 2025, we announced a restructuring plan designed to optimize our management structure to better serve our customers. In fiscal years 2024 and 2023, we announced restructuring plans that were both designed to reduce costs and expenses in response to macroeconomic conditions. These actions impact all three of our operating segments. The costs associated with these restructuring plans were not allocated to our operating segments' results; however, each operating segment will benefit from the future cost savings from these actions. When completed, the restructuring programs are expected to result in the reduction in annual cost of sales and operating expenses over the three operating segments. A summary of our aggregate liability related to the restructuring plans and the total restructuring expense since inception of those plans are shown in the table below: Workforce Reduction Consolidation of Excess Facilities Total (in millions) Balance at October 31, 2023 $ 31 $ 5 $ 36 Income statement expense 75 1 76 Non-cash settlements (7) (1) (8) Cash payments (86) (5) (91) Balance at October 31, 2024 $ 13 $ $ 13 Income statement expense 82 82 Non-cash settlements (18) (18) Cash payments (60) (60) Currency translation impact 1 1 Balance at October 31, 2025 $ 18 $ $ 18 Restructuring expense since inception of all plans: Fiscal Year 2025 Plan $ 81 Fiscal Year 2024 Plan $ 73 Fiscal Year 2023 Plan $ 50 Tota …

RestructuringAndRelatedActivitiesDisclosureTextBlock · excerpt; the full note is in the filing

"REVENUE The following table presents the companys total revenue and segment revenue disaggregated by geographical region: Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total (in millions) Year Ended October 31, 2025: Americas $ 1,337 $ 1,095 $ 374 $ 2,806 Europe 786 811 326 1,923 Asia Pacific 603 1,002 614 2,219 Total $ 2,726 $ 2,908 $ 1,314 $ 6,948 Year Ended October 31, 2024: Americas $ 1,157 $ 1,048 $ 368 $ 2,573 Europe 723 741 306 1,770 Asia Pacific 586 958 623 2,167 Total $ 2,466 $ 2,747 $ 1,297 $ 6,510 Year Ended October 31, 2023: Americas $ 1,333 $ 1,003 $ 396 $ 2,732 Europe 729 701 324 1,754 Asia Pacific 718 952 677 2,347 Total $ 2,780 $ 2,656 $ 1,397 $ 6,833 The following table presents the companys total revenue disaggregated by end markets and by revenue type: Years Ended October 31, 2025 2024 2023 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 2,507 $ 2,242 $ 2,433 Chemicals and Advanced Materials 1,561 1,495 1,543 Diagnostics and Clinical 1,029 964 966 Food 637 592 628 Academia and Government 540 567 601 Environmental and Forensics 674 650 662 Total $ 6,948 $ 6,510 $ 6,833 Revenue by Type Instrumentation $ 2,427 $ 2,354 $ 2,742 Non-instrumentation and other 4,521 4,156 4,091 Total $ 6,948 $ 6,510 $ 6,833 Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales fro …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

"SEGMENT INFORMATION Our President and Chief Executive Officer is the chief operating decision maker (""CODM""). The three operating segments were determined based primarily on how the CODM views and evaluates our operations. The CODM uses segment net revenue and income from operations to assess the performance of the segments by reviewing budget to actual variances on a monthly basis. The CODM also uses segment net revenue and income from operations when making decisions about allocating capital and personnel resources predominantly during the annual strategic planning process. The CODM does not evaluate the segments using asset or liability information. Description of Segments. We are a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment. Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment. The remaining divisions in our former Life Sciences and Applied Marke …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

"STOCKHOLDERS' EQUITY Stock Repurchase Programs On February 16, 2021 we announced that our board of directors had approved a share repurchase program (the ""2021 repurchase program"") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2021 repurchase program which commenced on February 18, 2021, authorized the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and had no fixed termination date. The 2021 repurchase program did not require the company to acquire a specific number of shares and could be suspended, amended or discontinued at any time. During the year ended October 31, 2023, we repurchased and retired 661,739 shares for $99 million, excluding excise taxes, under this authorization. On March 1, 2023, the 2021 repurchase program was terminated and the remaining authorization of $339 million expired. On January 9, 2023, we announced that our board of directors had approved a share repurchase program (the ""2023 repurchase program"") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2023 repurchase program authorized the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and had no fixed termination date. The 2023 repurchase program did not require the compan …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

"ACQUISITION Acquisition of Biocare On June 24, 2026, we acquired 100 percent of the outstanding capital stock of BC Midco I, Inc. (""Biocare"") for a net consideration paid of $950 million. Biocare is a leading provider of clinical and research solutions and is included within our Life Sciences and Diagnostics Markets segment. The acquisition of Biocare expands our pathology portfolio enabling us to better serve our pathology customers across clinical and research settings. As a result of the acquisition, Biocare became a wholly-owned subsidiary of Agilent. Accordingly, the results of Biocare are included in Agilent's condensed consolidated financial statements from the acquisition date. The Biocare acquisition was accounted for in accordance with the authoritative accounting guidance for business combinations. The acquired assets and assumed liabilities were recorded at their estimated fair values. We determined the estimated fair values with the assistance of valuations performed by a third-party specialist, discounted cash flow analyses and estimates made by management. We expect to realize revenue synergies, expand the existing sales channels and product development resources, and benefit from the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of Biocares net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transactio …

BusinessCombinationDisclosureTextBlock · excerpt; the full note is in the filing

WARRANTIES AND CONTINGENCIES Warranties We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheets. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below: Nine Months Ended July 31, 2026 2025 (in millions) Standard warranty accrual, beginning balance $ 28 $ 30 Accruals for warranties including change in estimates 46 37 Settlements made during the period (43) (39) Standard warranty accrual, ending balance $ 31 $ 28 Accruals for warranties due within one year $ 31 $ 28 Bank Guarantees Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $41 million and $39 million as of July 31, 2026 and October 31, 2025, respectively. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss. Contingencies We are involved in lawsui …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

The following table presents the companys total revenue and segment revenue disaggregated by geographical region: Three Months Ended July 31, 2026 2025 Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total (in millions) Revenue by Region Americas $ 369 $ 289 $ 103 $ 761 $ 316 $ 274 $ 93 $ 683 Europe 201 221 82 504 201 212 79 492 Asia Pacific 176 276 161 613 153 258 152 563 Total $ 746 $ 786 $ 346 $ 1,878 $ 670 $ 744 $ 324 $ 1,738 Nine Months Ended July 31, 2026 2025 Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total (in millions) Revenue by Region Americas $ 1,039 $ 851 $ 313 $ 2,203 $ 953 $ 805 $ 272 $ 2,030 Europe 618 658 264 1,540 568 594 235 1,397 Asia Pacific 500 794 474 1,768 450 754 456 1,660 Total $ 2,157 $ 2,303 $ 1,051 $ 5,511 $ 1,971 $ 2,153 $ 963 $ 5,087 The following table presents the companys total revenue disaggregated by end markets and by revenue type: Three Months Ended Nine Months Ended July 31, July 31, 2026 2025 2026 2025 (in millions) Revenue by End Markets Pharmaceutical and Biotechnology $ 707 $ 629 $ 2,010 $ 1,817 Chemicals and Advanced Materials 430 399 1,264 1,147 Diagnostics and Clinical 284 258 842 753 Food 158 157 471 472 Academia and Government 128 132 390 404 Environmental and Forensics 171 163 534 494 Total $ 1,878 $ 1,738 $ 5,511 $ 5,087 Reve …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

"SHARE-BASED COMPENSATION We account for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock options, restricted stock units, employee stock purchases made under our employee stock purchase plan (""ESPP"") and performance share awards granted to selected members of our senior management under the long-term performance plan (""LTPP"") based on estimated fair values. Performance Stock Units. We have two LTPP performance stock award programs, which are administered under the 2018 Stock Plan, for our executive officers and other key employees. Participants in our LTPP Total Stockholders Return (""TSR"") and LTPP Earnings Per Share (""EPS"") programs are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets for the programs are met. The LTPP-TSR awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the TSR set at the beginning of the performance period. The LTPP-EPS awards are based on the companys EPS performance over a three-year period. The performance targets for the LTPP-EPS for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. For LTPP awards granted in fiscal yea …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

"FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instruments categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 - applies …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2026: Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total (in millions) Goodwill as of October 31, 2025 $ 2,996 $ 1,168 $ 309 $ 4,473 Foreign currency translation impact 3 5 8 Goodwill arising from acquisitions 549 549 Goodwill as of July 31, 2026 $ 3,545 $ 1,171 $ 314 $ 5,030 The component parts of other intangible assets as of October 31, 2025 and July 31, 2026 are shown in the table below: Other Intangible Assets Gross Carrying Amount Accumulated Amortization Net Book Value (in millions) As of October 31, 2025 Purchased technology $ 1,484 $ 1,235 $ 249 Trademark/Trade name 199 181 18 Customer relationships 289 129 160 Backlog 9 2 7 Third-party technology and licenses 34 23 11 Total amortizable intangible assets $ 2,015 $ 1,570 $ 445 As of July 31, 2026 Purchased technology $ 1,633 $ 1,269 $ 364 Trademark/Trade name 201 185 16 Customer relationships 660 148 512 Backlog 9 3 6 Third-party technology and licenses 35 27 8 Total amortizable intangible assets $ 2,538 $ 1,632 $ 906 During the nine months ended July 31, 2026, we recorded additions of $549 million to goodwill and $520 million to other intangible assets in our Life Sciences and Diagnostics Markets segment related to our acquisition of Biocare. During the nine months ended July 31, 2026, there was no change in net book v …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

"INCOME TAXES For the three and nine months ended July 31, 2026, our income tax expense was $82 million with an effective tax rate of 18.5 percent and $210 million with an effective tax rate of 17.3 percent, respectively. For the three and nine months ended July 31, 2026, there were no significant discrete items. For the three and nine months ended July 31, 2025, our income tax expense was $30 million with an effective tax rate of 8.2 percent and $124 million with an effective tax rate of 12.5 percent, respectively. For the three and nine months ended July 31, 2025, our effective tax rate and the resulting provision for income taxes were impacted by the tax benefit of $28 million related to the release of tax reserves due to a remeasurement of the liability. In the U.S., tax years remain open back to the year 2022 for federal income tax purposes and 2021 for significant states. In other major jurisdictions where we conduct business, the tax years generally remain open back to the year 2016. With these jurisdictions and the U.S., it is reasonably possible that some tax audits may be completed over the next twelve months. However, management cannot provide a reasonably reliable estimate of the timing of any other future tax payments or change in unrecognized tax benefits, if any. The Organization for Economic Co-operation and Development (""OECD"") has introduced rules to establish a global minimum tax rate of 15 percent, commonly referred to as the Pillar Two rules. We have co …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

"LONG-TERM DEBT Senior Notes The following table summarizes our long-term senior notes: July 31, 2026 October 31, 2025 Amortized Principal Amortized Principal (in millions) 2027 Senior Notes $ 598 $ 597 2029 Senior Notes 498 497 2030 Senior Notes 498 498 2031 Senior Notes 846 845 2032 Senior Notes 594 2034 Senior Notes 594 593 Total Senior Notes $ 3,628 $ 3,030 2032 Senior Notes On June 25, 2026, we issued $600 million in aggregate principal amount senior notes (""2032 senior notes""). The 2032 senior notes were issued at 99.968 percent of their principal amount. The 2032 senior notes will mature on January 15, 2032, and bear interest at a fixed rate of 4.90 percent per annum. The interest is payable semi-annually in arrears on January 15 and July 15 of each year and payments will commence on January 15, 2027. All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilents other senior unsecured indebtedness. Other than the issuance of our 2032 senior notes, there have been no other changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the nine months ended July 31, 2026, as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2025. Other Loans We have two interest-free loans from the Strategic Innovation Fund (""SIF""). The loans are repayable in quarterly and yearly installments through 2040 …

LongTermDebtTextBlock · excerpt; the full note is in the filing

RETIREMENT PLANS AND POSTRETIREMENT PENSION PLANS Components of net periodic benefit cost (income). For the three and nine months ended July 31, 2026 and 2025, our net pension and postretirement benefit cost (income) were comprised of the following: Three Months Ended July 31, U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Postretirement Benefit Plans 2026 2025 2026 2025 2026 2025 (in millions) Service cost - benefits earned during the period $ $ $ 6 $ 6 $ $ Interest cost on benefit obligation 5 5 5 6 1 1 Expected return on plan assets (7) (6) (12) (12) (1) (1) Amortization of net actuarial (gain) loss (5) (7) Amortization of prior service benefit (1) Total net periodic benefit cost (income) $ (2) $ (1) $ (6) $ (7) $ $ (1) Nine Months Ended July 31, U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Postretirement Benefit Plans 2026 2025 2026 2025 2026 2025 (in millions) Service costbenefits earned during the period $ $ $ 14 $ 13 $ $ Interest cost on benefit obligation 14 15 17 17 3 3 Expected return on plan assets (19) (18) (37) (33) (4) (4) Amortization of net actuarial (gain) loss (19) (19) (1) (1) Amortization of prior service benefit (1) Total net periodic benefit cost (income) $ (5) $ (3) $ (25) $ (22) $ (2) $ (3) Settlement (gain) loss $ $ $ $ 14 $ $ The service cost component is recorded in cost of revenue and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (ex …

PensionAndOtherPostretirementBenefitsDisclosureTextBlock · excerpt; the full note is in the filing

"RESTRUCTURING AND OTHER RELATED COSTS Summary of Restructuring Plans. In fiscal years 2026 and 2025, we announced two separate restructuring plans designed to optimize our management structure to better serve our customers. These actions impact all three of our business segments. The costs associated with these restructuring plans were not allocated to our business segments' results; however, each business segment will benefit from the future cost savings from these actions. When completed, the restructuring programs are expected to result in the reduction in annual cost of revenues and operating expenses over the three business segments. A summary of our aggregate liability relating to the fiscal year 2026 and 2025 restructuring plans and the total restructuring expense since inception of each plan are shown in the table below: Workforce Reduction Total (in millions) Balance at October 31, 2025 $ 18 Income statement expense 20 Non-cash settlement (accelerated share-based compensation expense) (3) Cash payments (19) Balance at January 31, 2026 $ 16 Income statement expense 8 Non-cash settlement (accelerated share-based compensation expense) (3) Cash payments (16) Balance at April 30, 2026 $ 5 Income statement expense 15 Non-cash settlement (accelerated share-based compensation expense) (1) Cash payments (6) Balance at July 31, 2026 $ 13 Restructuring expense since inception of plan: Fiscal Year 2026 Plan $ 15 Fiscal Year 2025 Plan 109 Total restructuring expense since incept …

RestructuringAndRelatedActivitiesDisclosureTextBlock · excerpt; the full note is in the filing

"REVENUE The following table presents the companys total revenue and segment revenue disaggregated by geographical region: Three Months Ended July 31, 2026 2025 Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total (in millions) Revenue by Region Americas $ 369 $ 289 $ 103 $ 761 $ 316 $ 274 $ 93 $ 683 Europe 201 221 82 504 201 212 79 492 Asia Pacific 176 276 161 613 153 258 152 563 Total $ 746 $ 786 $ 346 $ 1,878 $ 670 $ 744 $ 324 $ 1,738 Nine Months Ended July 31, 2026 2025 Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total Life Sciences and Diagnostics Markets Agilent CrossLab Applied Markets Total (in millions) Revenue by Region Americas $ 1,039 $ 851 $ 313 $ 2,203 $ 953 $ 805 $ 272 $ 2,030 Europe 618 658 264 1,540 568 594 235 1,397 Asia Pacific 500 794 474 1,768 450 754 456 1,660 Total $ 2,157 $ 2,303 $ 1,051 $ 5,511 $ 1,971 $ 2,153 $ 963 $ 5,087 The following table presents the companys total revenue disaggregated by end markets and by revenue type: Three Months Ended Nine Months Ended July 31, July 31, 2026 2025 2026 2025 (in millions) Revenue by End Markets Pharmaceutical and Biotechnology $ 707 $ 629 $ 2,010 $ 1,817 Chemicals and Advanced Materials 430 399 1,264 1,147 Diagnostics and Clinical 284 258 842 753 Food 158 157 471 472 Academia and Government 128 132 390 404 Environmental and Forensics 171 163 534 494 Total $ 1,878 $ 1,738 $ 5,511 $ 5 …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

"SEGMENT INFORMATION Our President and Chief Executive Officer is the chief operating decision maker (""CODM""). The three operating segments were determined based primarily on how the CODM views and evaluates our operations. The CODM uses segment net revenue and income from operations to assess the performance of the segments by reviewing budget to actual variances on a monthly basis. The CODM also uses segment net revenue and income from operations when making decisions about allocating capital and personnel resources predominantly during the annual strategic planning process. The CODM does not evaluate the segments using asset or liability information. Description of Segments. We are a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. A description of our three reportable segments is as follows: Our Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our liquid chromatography and liquid chromatography mass spectrometry businesses enable customers in the clinical and life sciences research areas to i …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

"STOCKHOLDERS' EQUITY Stock Repurchase Programs On January 9, 2023, we announced that our board of directors had approved a share repurchase program (the ""2023 repurchase program"") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2023 repurchase program authorized the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and had no fixed termination date. The 2023 repurchase program did not require the company to acquire a specific number of shares and could have been suspended, amended or discontinued at any time. The 2023 repurchase program commenced on March 1, 2023 and was completed as of September 2025. During the three and nine months ended July 31, 2025, we repurchased and retired 737,474 shares for $85 million, excluding applicable excise taxes and 2.734 million shares for $340 million, excluding applicable excise taxes, respectively, under this authorization. On May 29, 2024, we announced that our board of directors had approved a share repurchase program (the ""2024 repurchase program"") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2024 repurchase program authorizes the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and has no fixed termination da …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing